BACKGROUND:
In Canada, many health authorities recommend that primary care physicians (PCP) stay involved throughout their patients' cancer journey to increase continuity of care. Few studies have focused on patient and physician expectations regarding PCP involvement in cancer care. OBJECTIVE: To compare lung cancer patient, PCP and specialist expectations regarding PCP involvement in coordination of care, emotional support, information transmission and symptom relief at the different phases of cancer. DESIGN: Canadian survey of lung cancer patients, PCPs and cancer specialists PARTICIPANTS: A total of 395 patients completed questionnaires on their expectations regarding their PCP participation in several aspects of care, at different phases of their cancer. Also, 45 specialists and 232 community-based PCP involved in these patients' care responded to a mail survey on the same aspects of cancer care. RESULTS: Most specialists did not expect participation of the PCP in coordination of care in the diagnosis and treatment phases (65% and 78% respectively), in contrast with patients (83% and 85%) and PCPs (80% and 59%) (p<0.0001). At these same phases, the best agreement among the 3 groups was around PCP role in emotional support: 84% and more of all groups had this expectation. PCP participation in symptom relief was another shared expectation, but more unanimously at the treatment phase (p=0.85). In the advanced phase, most specialists expect a major role of PCP in all aspects of care (from 81% to 97%). Patients and PCP agree with them mainly for emotional support and information transmission. CONCLUSION: Lung cancer patient, PCP and specialist expectations regarding PCP role differ with the phase of cancer and the specific aspect of cancer care.
INTRODUCTION
Cancer patients have to consult many health professionals, leading to fragmented care. Primary care physicians (PCP) involvement is frequently interrupted when patients are followed by oncology teams. [1] [2] [3] [4] [5] At the treatment phase, patients often consider specialists as their regular physician, 6, 7 leading to a loss of continuity of care with their PCP. 2, 6, [8] [9] [10] [11] PCPs may feel disengaged in their role 12, making it difficult to take back the responsibility for patient care at the advanced phase 13 , especially without access to all relevant information. 2, 4, 5, 7, 11, [13] [14] [15] [16] [17] [18] [19] As PCPs are recognized as key players in providing continuous and comprehensive care, [20] [21] [22] [23] Eligible patients were informed of the study by the oncology team. Those who agreed to be contacted by the research team were invited to participate and signed an informed consent form. Basic information on non-participants was kept to compare them with participants.
Patients were followed for a maximum of 18 months, either at 3 or 6-month intervals, whether they had metastasis or not, in order to take into account their different survival. This strategy was chosen to ensure that patients with the most aggressive types of lung cancer would be followed closely enough to question them at different phases, without losing them to follow-up (if their condition deteriorated or if they died between two data collections); in addition, patients with the best prognosis would not be questioned too often during the same cancer phase (if their condition stayed stable). At baseline, patients were met during 45 minutes, either at the oncology clinic or at home, depending on their preference. Subsequent interviews lasted 20 to 30 minutes and took place at the oncology clinic, at home or over the phone. Their medical charts were reviewed at baseline and prior to each interview to determine if metastasis had developed and to ascertain the cancer phase.
When patients had a regular PCP, a letter was mailed to them to inform them of their patient's participation in the study and to invite them to complete a questionnaire. A mailed recall was sent to non-respondents three weeks later. If PCPs had more than one participating patient, they completed the questionnaire only once, but they were informed of each of their patients who participated. Specialists involved in lung cancer at the study hospitals (pulmonologists, hematologists/oncologists, thoracic surgeons) were also invited to complete a questionnaire. This study was approved by the Research Ethics Committee of Laval University and of all study hospitals.
Patient Questionnaire
At baseline, patients completed questionnaires regarding their sociodemographics, lung cancer history, functional status (Eastern Cooperative Oncology Group Performance Status Scale-ECOG) 38 Subsequently, categories 1 and 2 were regrouped to indicate PCPs "not involved", and categories 3 and 4 were regrouped to identify those "involved". A test-retest analysis of this instrument was performed on 20 patients at two-week interval and, based on concordance testing, there was no significant difference between the two sets of response for all variables (p=0.31 to 0.99). At subsequent interviews, patients completed the same questionnaires on their functional status and their PCP expected involvement in the same aspects of care as those assessed at baseline. Data were classified according to three cancer phases: diagnosis, treatment and advanced/terminal. Determination of cancer phases was based on information from the medical chart, except for the advanced/terminal phase, which was defined as a score of 3 or 4 on the ECOG scale. This decision was made to avoid misclassification of patients, considering the lack of consensus in the literature to precisely define this phase from clinical predictors.
Physician Questionnaire
PCPs completed a questionnaire on their personal and professional characteristics and their actual and desired involvement at the same cancer phases and for the same aspects of care as those assessed with patients. The first part of the questionnaire was derived from the 2004 Canadian National Family Physician Workforce Survey 43 and, in the second part, questions were formulated to mirror patients' ones, in order to compare the two group responses. Similarly, specialists involved in participating patients care completed a questionnaire on their personal and professional characteristics and their expectations regarding PCP role at the same cancer phases, using the same questions than those asked to patients and PCPs.
Statistical Analysis
Baseline patient and physician characteristics were summarized with descriptive statistics. . It was impossible to do the same with patients and oncologists since no oncologist was assigned to specific patients. Few PCPs (19%) have cared for more than one patient and contributed more than once to the analysis. For PCPs with more than one participating patient, a subset analysis was performed with only one matched patient-PCP randomly selected to limit the data set to one response per PCP. This analysis was compared to the one allowing for multiple patients matched to a PCP, and results were similar. An α level of 0.05 was used as significance threshold. All statistical analyses were performed using the SAS software, version 9.1 (SAS Institute Inc., Cary, NC).
RESULTS
From the 695 eligible patients, a total of 395 were recruited (participation rate 56.8%). No difference was found between participants and non-participants (p=0.5) for the type of lung cancer. More women refused to participate than men (p= 0.05). Participants were slightly younger on average than non-participants (63.4 vs 65.5; p=0.02). Figure 1 shows patients' participation in the study. Over the study period, patients' condition did not progress similarly for everyone. Four scenarios of evolution were found: 1) patients died or dropped out before their second data collection, so they only contributed to the diagnostic phase (n=75); 2) patients were interviewed at baseline and during the treatment phase, but did not reach the advanced phase (either because they remained stable or died before reaching that phase), so they contributed only to the diagnostic and treatment phases (n=281); 3) patients were interviewed at all three phases (n =27); 4) patients were interviewed at baseline, but their cancer progressed rapidly and their second interview was at the advanced phase (n =12). participating to an on-call service for their patients. A large proportion (75.4%) was involved in palliative care and more than half were doing house calls (54.3%), which was more frequent than PCPs from the 2007 NPS. 45 Finally, a proportion of 70.3% of the 64 specialists involved in lung cancer care in the study hospitals completed the questionnaire. Almost half of them were pulmonologists. Compared to the 2007 NPS 46,47, participating specialists had slightly more years in practice.
Patient and Physician Characteristics

PCP Involvement in the Follow-up of Patients with Lung Cancer
Throughout the cancer care trajectory, most PCPs reported being involved at the diagnostic (87.8%) and advanced (70.1%) phases of cancer, but fewer were involved at the treatment phase (43.7%). When questioned about their pattern of care with the oncology team during the treatment phase, 48.9% of PCPs reported shared care, while 45.4% mentioned a parallel pattern of care, and 5.7% felt left out (sequential care). These results differ from patients' perception of their PCP pattern of care at the same cancer phase. As shown in Figure 2 , patients perceive less frequently a shared pattern of care between their PCP and the oncology team.
Expectations Regarding PCP Involvement in Lung
Cancer Patients' Follow-up Figure 3 shows certain discrepancies between patient, PCP and oncologist respective expectations regarding PCP role at the different cancer phases. Most patients would like a continuous involvement of their PCP at all phases, mainly for coordination of care and emotional support. A majority of PCPs wished to stay involved in all aspects of care, but, at the treatment phase, a lower proportion of them wanted to be involved in coordination of care. Oncologists recognized a role for PCPs mainly at the advanced phase. But, at the diagnostic and treatment phases, only a few saw PCPs involved in coordination of care, compared to patients and PCPs (p<0.0001). More than 80% of PCPs considered they could be involved in transmission of information to patients, but a smaller proportion of oncologists and patients shared that view, particularly at the diagnostic (p <0.0001) and treatment (p <0.01) phases. At all phases of cancer, emotional support was the aspect of care where the three groups * Proportion of PCP involved in each setting calculated from the total number of participants (N=232), but globally, 175 (75.4%) of them reported being involved in palliative care; some physicians were active in palliative care in more than one setting agreed the most. There was also some agreement between them regarding PCP role in symptom relief, but mainly at the treatment phase (p=0.85). Table 3 shows matched data between PCPs and their patients. Agreements in expectations between patients and their matched PCPs regarding PCP role in cancer care ranged from 26% to 72%, with generally the highest concordance rates found at the advanced phase.
DISCUSSION
This study shows a significant disconnect between patient, PCP and oncologist expectations regarding PCP involvement at all phases of cancer, but predominantly at the diagnostic and treatment phases. PCP participation in coordination of care and transmission of information seemed to be the aspects where the most significant discordance was found. 18, 35 . In other studies, oncologists reported a willingness to share patient follow-up with PCPs, 8 but they insisted on the need to better define their respective responsibilities. 36 Beside the potential information bias mentioned earlier, this study has some other limitations. Patient participation rate was rather low, but it compares well with other studies conducted with such vulnerable population 5, 31, 50 . Moreover, few patients withdrew, their main reasons for dropping out being death or cancer recurrence, which were inevitable in this population. PCP and oncologist participation rates were higher than in other surveys 5,30,31,34, but their characteristics were slightly different from the ones found in the 2007 NPS, considered as representative of the Canadian medical workforce. However, since findings from this study are in agreement with those from other surveys 31,37,48, the situation described here is probably close to reality. Another limitation relies on the exclusive recruitment of lung cancer patients, which makes uncertain the generalizability to patients with other types of cancer. However, since the cohort included patients with a varied distribution in age, gender, stage at diagnosis and treatment, it gives insights into patient preferences on cancer follow-up care that may also apply to other cancers. Also, while patients reported how they perceived their own PCP involvement in their care, PCP questions were not directed to one particular patient. It is possible that some of their answers might have been different if they were answering about a specific patient. Nevertheless, a minority of PCPs had more than one patient recruited in the study. Finally, this research focused only on four aspects of care, but they are key domains of cancer care.
In summary, this study highlights the existence of a large gap between patient, PCP and specialist expectations toward PCP involvement in the cancer care trajectory. It reinforces 
